论文部分内容阅读
A novel regulatory variant of HMGB1 gene is associated with the disease progression in chronic hepat
【机 构】
：
Institute of Infectious Diseases, Southwest Hospital, the Third Military Medical University, Chongqi
【出 处】
：
第三届全国病毒性肝炎慢性化重症化基础与临床研究进展学术会议
【发表日期】
：
2013年7期
其他文献
目的：探讨聚乙二醇干扰素a-2a(PEG-INFa-2a)冶疗HBeAg阳性慢性乙型肝炎的疗效和安全性.方法：84例CHB患者按1∶1比例随机分配到治疗组和对照组.治疗组(42例)予PEG-INFa-2a180μg皮下注射,每周1次,疗程48周.对照组(42例)予普通干扰素(IFN)300万单位,皮下注射,隔日1次,疗程48周.治疗结束后再随访24周.结果：在疗程结束后24周时,两组HBeAg和H
目的：分析病毒性肝炎与脂肪肝炎患者LSM的差异及其影响因素.方法：分析963例脂肪肝及病毒性肝炎患者LSM与年龄、性别、病因、临床类型及疾病严重程度的关系.结果：1)脂肪肝组LSM最高,其次是乙肝、丙肝和其他病毒肝炎相近.2)乙肝LSM随年龄增加而增加,丙肝、脂肪肝及其他病毒肝炎LSM未随年龄增加而增加.3)乙肝男性LSM明显高于女性,脂肪肝及其他病毒肝炎男性略高于女性,丙肝男略低于女性.4)慢性
目的:探讨核苷类药物替比夫定对肝癌细胞株HepG2肿瘤干细胞标志分子CD133和甲胎蛋白(AFP)的影响.方法:本研究以HepG2细胞为实验细胞,实验分为两组:实验组(与替比夫定共育组)和对照组(单纯细胞组).实验组加入含替比夫定(10umol/L)培养液与细胞共育,对照组只加不含替比夫定细胞培养液培养.隔天更换细胞培养液.培养细胞至80-90％铺满培养瓶时,收集细胞.1)4×105细胞/ml被用
A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma:a m
Backgrounds: Glypican-3(GPC-3) has been reported as one of the most promising serum markers for hepatocellular carcinoma (HCC), while several studies have conflicting results for the diagnostic accura
本研究拟采用营养风险筛查(nutritional risk screening NRS-2002)表为工具，调查住院终末期肝病患者营养风险，以期初步了解此类患者的普遍营养状态、相关危险因素，并探讨可能的干预措施，研究表明，男性患者在三种营养风险级别(无风险、有风险、高度风险)中均占多数，提示终末期肝病患者中男性占大多数，但营养风险分布男女性基本一致。
Quantitative hepatitis B surface antigen titers in Chinese chronic hepatitis B patients over 4 years
Background & Aims: The clinical value of quantitative hepatitis B surface antigen (qHBsAg) titer in patients taking nucleot(s)ide analogs(NAs) is still controversial.This study aims to investigate the
会议
Relationship between polymophisms of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene and hepati
Interference with novel gene KCTD9inhibits NK cell activation and ameliorates Murine Hepatitis Virus
Background/aims:Our previous reports, both experimental and human studies, have shown the novel geneKCTD9 contributed to liver injurythrough hepatic NK cell activation in HBV induced acute-on-chronic
会议
Nucleoside Analogs Prevent Disease Progression in HBV-Related Acute-on-Chronic Liver Failure:Validat
Background and aims Hepatitis B related acute-on-chronic liver failure (HBV-ACLF) has a poor prognosis with very high mortality.Experience in nucleoside analogues treated patients with HBV-ACLF is lim
会议